Predictors of a prolonged course of community-acquired pneumonia

Authors

  • V. V. Syvolap Zaporizhzhia State Medical University,
  • L. O. Kurilets Zaporizhzhia State Medical University,
  • A. O. Yarosh Zaporizhzhia State Medical University,
  • M. S. Potapenko Zaporizhzhia State Medical University,

DOI:

https://doi.org/10.14739/2310-1210.2017.2.95673

Keywords:

pneumonia, prolonged course, рredictors

Abstract

Almost 30% of patients with community-acquired pneumonia have prolonged duration and association with increase of complications, length of hospital stay, treatment costs and mortality.

Aim: To find the predictors of community-acquired pneumonia prolonged course.

Material and Methods. 100 patients with community-acquired pneumonia group 3 were included in the randomized, controlled, prospective open study. The average age of patients was 43,63 ± 14,58 years, 59% were men. Patients were divided into two groups depending on the character and severity of pneumonia: prolonged course (more than 21 days) was in 15 patients, other (n = 85) recovered within 3 weeks. All patients have been examined on the first day of hospitalization by general clinical and X-ray examination, laboratory tests, immunogram, ADP-induced platelet aggregation, the study of respiratory function, transthoracic echocardiography; glomerular filtration rate was calculated by Cockcroft-Gault formula.

Results and Discussion. Patients with community-acquired pneumonia group 3with a prolonged duration represented 15% of the total number involved in our study patients, and had 65% more length of hospital stay. According to logistic regression model the predictors of prolonged duration of community-acquired pneumonia are a fasting blood sugar, glomerular filtration rate by Cockcroft-Gault, time of ADP-induced platelet aggregation, body mass index, heart rate, blood flow in the pulmonary artery, the reserve volume of inhalation. There are independent risk factors for community-acquired pneumonia with prolonged duration: blood glucose level less than 4.8 mmol / L, glomerular filtration rate less than 82 mL / min, body mass index less than23.12 kg / m2, the time of ADP -induced platelet aggregation is 370 s.

Conclusions. Independent risk factors for community-acquired pneumonia with prolonged duration are: blood glucose level (Odds Ratio = 27,87; p = 0,037), glomerular filtration rate (OR = 16,95; p = 0,011), body mass index (OR = 19,72; p = 0,030), time of ADP-induced platelet aggregation (OR = 37,02; p = 0,011).

References

  1. Mittl, R. L., Schwab, R. J., Duchin, J. S., Goin, J. E., Albeida, S. M., & Miller, W. T. (1994). Radiographic resolution of community-acquired pneumonia. Am J Respir Crit Care Med, 149(630), 5. doi: 10.1164/ajrccm.149.3.8118630.
  2. Kirtland, S. N., & Winterbauer, R. H. (1991) Slowly resolving, chronic, and recurrent pneumonia. Clin. Chest. Med., 12, 303–318.
  3. Bruns, A. H., Oosterheert, J. J., Prokop, M., Lammers, J. W., Hak, E., & Hoepelman, A. I. (2007). Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia. Clin Infect Dis, 45(983), 91. doi: 10.1086/521893.
  4. Synopal´nikov, A. I., & Zajtsev, A. A. (2009). Medlenno razreshayushchayasya/nerazreshayushchayasyia vnebol´nichnaya pnevmoniya [Slowly resolved/unresolved community-acquired pneumonia]. Rossijskij medicinskij zhurnal, 5, 361–367. [in Russian].
  5. (2008) Nakaz MOZ Ukrainy «Pro zatverdzhennia klinichnykh protokoliv nadannia medychnoi dopomohy za spetsialnistiu «Pulmonolohiia» vid 19.03.2007 r. №128 [Order MOZ of Ukraine “On approval of clinical protocols of medical care in the specialty "Pulmonology", from March, 19. 2007 №128]. Likarska sprava, 5/6, 108–130. [in Ukrainian].
  6. Gerasimov, I. G. (2006). Funkcional´naya neodnorodnost´ nejtrofilov [Functional heterogeneity of neutrophils]. Klinicheskaya laboratornaya diagnostika, 2, 34–36. [in Russian].
  7. Born, G. V. (2005). Light on platelets. J. Physiol, 568(3), 713–714.
  8. Arancibia, F., Ewig, S., Martinez, J. A., Ruiz, M., Bauer, T., Marcos, M. A., et al. (2000). Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am. J. Respir. Crit. Care Med., 162(1), 154–160. doi: 10.1164/ajrccm.162.1.9907023.
  9. Genné, D., Sommer, R., Kaiser, L., Saaïdia, A., Pasche, A., Unger, P. F., & Lew, D. (2006). Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis., 25(3), 159–166. doi: 10.1007/s10096-006-0113-3.
  10. Menéndez, R., Torres, A., Zalacaín, R., Aspa, J., Martín Villasclaras, J. J., Borderías, L., et al. (2004). Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax, 59(11), 960–965. doi: 10.1136/thx.2003.017756.
  11. Rosón, B., Carratalà, J., Fernández-Sabé, N., Tubau, F., Manresa, F., & Gudiol, F. (2004). Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch. Intern. Med, 164(5), 502–508. doi: 10.1001/archinte.164.5.502.
  12. Menendez, R., Torres, A., Rodriguez de Castro, F., Zalacain, R., Aspa, J., Martin Villasclaras, J. J., et al. (2004). Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis, 39, 1783–1790. doi: 10.1086/426028.
  13. Hoogewerf, M., Oosterheert, J. J., Hak, E., Hoepelman, I. M., & Bonten, M. J. (2006). Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia. Clin Microbiol Infect, 12, 1097–1104. doi: 10.1111/j.1469-0691.2006.01535.x.
  14. Kolditz, M., Ewig, S., & Hoffken, G. (2013). Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J, 41, 974–984. doi: 10.1183/09031936.00104412.
  15. Bender, M. T., & Niederman, M. S. (2016). Outcomes in community-acquired pneumonia. Curr Opin Pulm Med, 22(3), 235–242. doi: 10.1097/MCP.0000000000000257.
  16. Brown, A. O., Millett, E. R., Quint, J. K., & Orihuela, C. J. (2015). Cardiotoxicity during invasive pneumococcal disease. Am. J. Respir. Crit. Care Med, 191, 739–745. doi: 10.1164/rccm.201411-1951PP.
  17. Prina, E., Ferrer, M., Ranzani, O. T. , Polverino, E., Cillóniz, C., Moreno, E., et al. (2013). Thrombocytosis is a marker of poor outcome in community-acquired pneumonia. Chest, 143, 767–775. doi: 10.1378/chest.12-1235.
  18. Mirsaeidi, M., Peyrani, P., Aliberti, S., Filardo, G., Bordon, J., Blasi, F., & Ramirez, J. A. (2010). Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia. Chest, 137, 416–420. doi: 10.1378/chest.09-0998.
  19. Semple, J. W., Italiano, J. E., & Freedman, J. (2011). Platelets and the immune continuum. Nat Rev Immunol, 11, 264–274. doi: 10.1038/nri2956.
  20. Harrison, M. T., Short, P., Williamson, P. A., Singanayagam, A., Chalmers, J. D., & Schembri, S. (2014). Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax, 69, 609–615. doi: 10.1136/thoraxjnl-2013-203996.
  21. Brown, A. O., Millett, E. R., Quint, J. K., & Orihuela, C. J. (2015). Cardiotoxicity during invasive pneumococcal disease. Am. J. Respir. Crit. Care Med., 191, 739–745. doi: 10.1164/rccm.201411-1951PP.
  22. Brogly, N., Devos, P., Boussekey, N., Georges, H., Chiche, A., & Leroy, O. (2007). Impact of thrombocytopenia on outcome of patients admitted to ICU for severe community-acquired pneumonia. J Infect, 55, 136–140. doi: 10.1016/j.jinf.2007.01.011.
  23. Chalmers, J. D., Singanayagam, A., & Hill, A. T. (2008). C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am. J. Med., 121, 219–225. doi: 10.1016/j.amjmed.2007.10.033.
  24. Almirall, J., Bolíbar, I., Toran, P., Pera, G., Boquet, X., Balanzó, X., & Sauca G. (2004). Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest, 125(4), 1335–1342. doi:10.1378/chest.125.4.1335.
  25. Müller, B., Harbarth, S., Stolz, D., Bingisser, R., Mueller, C., Leuppi, J., et al. (2007). Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis, 7, 10. doi: 10.1186/1471-2334-7-10.
  26. Schuetz, P., Suter-Widmer, I., Chaudri, A., Christ-Crain, M., Zimmerli, W., & Mueller, B. (2011). Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J, 37, 384–392. doi: 10.1183/09031936.00035610.
  27. Menéndez, R., Cavalcanti, M., Reyes, S., Mensa, J., Martinez, R., Marcos, M. A., et al. (2008). Markers of treatment failure in hospitalised community acquired pneumonia. Thorax, 63(5), 447-452. doi: 10.1136/thx.2007.086785.
  28. Capelastegui, A., España, P. P., Quintana, J. M., Areitio, I., Gorordo, I., Egurrola, M., & Bilbao, A. (2006). Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J, 27(1), 151–157. doi: 10.1183/09031936.06.00062505.
  29. Metersky, M. L., Ma, A., Bratzler, D. W., & Houck, P. M. (2004). Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med, 169(3), 342–347. doi: 10.1164/rccm.200309-1248OC.
  30. Arnold, F. W., Ramirez, J. A., McDonald, L. C., & Xia, E. L. (2003).Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest, 124(1), 121–124. doi:10.1378/chest.124.1.121.

Downloads

How to Cite

1.
Syvolap VV, Kurilets LO, Yarosh AO, Potapenko MS. Predictors of a prolonged course of community-acquired pneumonia. Zaporozhye Medical Journal [Internet]. 2017Mar.14 [cited 2026Jun.7];19(2). Available from: https://zmj.zsmu.edu.ua/article/view/95673

Issue

No. 2 (2017)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons